Amid a surge in mental health disorders and growing demand for psychedelic drugs for therapeutic use, the global psychedelic drugs market is projected to hit $6.4 billion in 2034, exhibiting a steady compound annual growth rate (CAGR) of 12.2% from 2024 to 2034. One stock that’s well-positioned to benefit from this trend is small-cap biotech company Mind Medicine (MNMD), also known as MindMed. In a recent milestone, the company announced its inclusion in the benchmark Russell 2000 Index (RUT) of small-cap stocks. This recognition not only underscores Mind Medicine’s commitment to advancing tre…